LH
LHU.F LeMaitre Vascular Inc
- Market cap
- EUR 1.59B
- P/E
- 29.3x
- P/B
- 4.11x
- ROE
- 14.7%
- Dividend yield
- 1.29%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LHU.F undervalued?
Graham numberLHU.F trades 131.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LeMaitre Vascular Inc fundamental analysis
No fundamental analysis for LeMaitre Vascular Inc yet.
LeMaitre Vascular Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LeMaitre Vascular Inc
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusio…
Full company profileLeMaitre Vascular Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LeMaitre Vascular Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 89.2M | 101M | 106M | 117M | 129M | 154M | 162M | 193M | 220M | 250M | 273M |
| Gross Profit | 62.9M | 70.7M | 73.9M | 79.9M | 84.6M | 101M | 105M | 127M | 151M | 179M | 197M |
| Operating Income | 16.3M | 21.1M | 20.7M | 21.2M | 28.3M | 36.4M | 29.9M | 37.2M | 52.3M | 67.9M | 74.5M |
| EBITDA | - | 25.2M | 32.8M | 27.1M | 37.1M | 36.5M | 27.5M | 49.0M | 66.7M | 90.8M | 98.1M |
| Net Income | 10.6M | 17.2M | 22.9M | 17.9M | 21.2M | 26.9M | 20.6M | 30.1M | 44.0M | 57.7M | 63.7M |
| EPS | - | 0.89 | 1.17 | 0.89 | 1.03 | 1.23 | 0.93 | 1.35 | 1.95 | 2.54 | 2.78 |
| Balance Sheet | |||||||||||
| Total Assets | 102M | 126M | 153M | 188M | 253M | 293M | 310M | 347M | 552M | 616M | 656M |
| Total Liabilities | 14.4M | 16.6M | 22.9M | 40.2M | 80.2M | 38.7M | 42.3M | 48.9M | 215M | 222M | 224M |
| Shareholders' Equity | 87.5M | 110M | 130M | 148M | 173M | 254M | 268M | 298M | 337M | 394M | 432M |
| Cash & Short-term Investments | 24.3M | 19.1M | 26.3M | 11.8M | 26.8M | 13.9M | 19.1M | 24.3M | 25.6M | 28.2M | 27.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.9M | 22.9M | 19.5M | 14.2M | 34.8M | 35.1M | 25.4M | 36.8M | 44.1M | 81.3M | 70.7M |
| Capital Expenditure | 2.84M | 6.42M | 3.05M | 3.76M | 2.98M | 4.88M | 3.23M | 7.27M | 6.96M | 6.78M | 9.91M |
| Free Cash Flow | - | 16.5M | 16.5M | 10.4M | 31.8M | 30.2M | 22.1M | 29.5M | 37.2M | 74.5M | 60.8M |
| Ratios | |||||||||||
| ROE | 12.1% | 15.6% | 17.6% | 12.1% | 12.3% | 10.6% | 7.7% | 10.1% | 13.1% | 14.7% | 14.7% |
| ROA | 10.4% | 13.6% | 15.0% | 9.5% | 8.4% | 9.2% | 6.6% | 8.7% | 8.0% | 9.4% | 9.7% |
| Net Profit Margin | 11.9% | 17.0% | 21.7% | 15.3% | 16.4% | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% | 23.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LeMaitre Vascular Inc dividends
- Dividend yield
- 1.29%
- Forward dividend
- 0.90 EUR
- Payout ratio
- 31.4%
- Ex-dividend date
- Nov 19, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 18.1M | 0.80 | 31.4% |
| 2024 | USD 14.4M | 0.64 | 32.6% |
| 2023 | USD 12.4M | 0.56 | 41.3% |
| 2022 | USD 11.0M | 0.50 | 53.2% |
| 2021 | USD 9.34M | 0.43 | 34.7% |
| 2020 | USD 7.70M | 0.37 | 36.3% |
| 2019 | USD 6.74M | 0.33 | 37.6% |
| 2018 | USD 5.45M | 0.28 | 23.7% |
| 2017 | USD 4.18M | 0.22 | 24.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LeMaitre Vascular Inc
- Insiders 6.52%
- Institutions 93.48%
- Public & others 0.00%
- Shares outstanding 22.9M
- Free float 21.3M
LeMaitre Vascular Inc company profile
- Company name
- LeMaitre Vascular Inc
- Ticker
- LHU.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 646
- Fiscal year end
- December
- Address
- 63 Second Avenue, Burlington, MA, United States, 01803
- Phone
- 781 221 2266
- Website
- lemaitre.com
About LeMaitre Vascular Inc
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
LeMaitre Vascular Inc management
10- Mr. George W. LeMaitreChairman & CEO · born 1965
- Mr. David B. RobertsPresident & Director · born 1964
- Mr. Dorian P. LeBlanc CPAChief Financial Officer · born 1975
- Mr. Trent G. KamkeSenior Vice President of Operations · born 1971
- Dr. George D. LeMaitre FACS, M.D.Founder and Chairman of Scientific Advisory Board · born 1934
- Ms. Laurie A. Churchill J.D.Chief Legal Officer · born 1971
- Mr. Daniel J. MumfordSenior Director of Human Resources · born 1982
- Mr. Jonathan W. NgauSenior Vice President of Information Technology · born 1974
- Mr. Maik D. HelmersSenior Vice President of Sales ? Central Europe · born 1974
- Mr. Ryan H. ConnellySenior Vice President of Advanced Manufacturing Engineering · born 1977